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The ability of superoxide anion (0;) from stimulated 
human neutrophils (PMNs) to release ferrous iron (Fe2+) 
from transferrin was assessed. At pH 7.4, unstimulated 
PMNs released minimal amounts of 0; and failed to fa- 
cilitate the release of Fe2+ from holosaturated transferrin. 
In contrast, incubation of phorbol myristate acetate 
(PMA)-stimulated PMNs with holosaturated transferrin 
at pH 7.4 enhanced the release of Fe2+ from transferrin 
eightfold in association with marked generation of 0,. 
The release of Fe2+ was inhibited by addition of super- 
oxide dismutase (SOD), indicating that the release of Fe2+ 
was dependent on PMN-derived extracellular 0;. In 
contrast, at physiologic pH (7.4), incubation of transfer- 
rin at physiological levels of iron saturation (e.g. 32%) 
with unstimulated or PMA stimulated PMNs failed to fa- 
cilitate the release of Fe2+. The effect of decreasing the 
pH on the release of Fe2+ from transferrin by PMN-de- 
rived 0; was determined. Decreasing the pH greatly fa- 
cilitated the release of Fe’+ from both holosaturated 
transferrin and from transferrin at physiological levels 
of iron saturation by PMN-derived 0;. Release of Fe2+ 
occurred despite a decrease in the amount of extracellular 
0, generated by PMNs in an acidic environment. These 
results suggest that transferrin at physiologic levels of 
iron saturation may serve as a source of Fe2+ for biolog- 
ical reactions in disease states where activated phago- 
cytes are present and there is a decrease in tissue pH. 
The unbound iron could participate in biological reactions 
including promoting propagation of lipid peroxidation 
reactions or hydroxyl radical formation following re- 
action with phagocytic cell-derived hydrogen peroxide. 
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at sites of inflammation (1). This may occur secondary 
to the promotion of lipid peroxidation reactions or iron- 
catalyzed hydroxyl radical (‘OH) formation via a Fenton 
reaction. However, under normal physiologic conditions, 
free iron does not exist in plasma or extracellular fluids 
and is not readily available for participation in biological 
reactions. Iron (Fe3+) is carried in the vertebrate blood- 
stream bound to transferrin in a ternary complex involv- 
ing iron, transferrin, and bicarbonate (2-6) and is unable 
to promote oxidant-induced tissue injury in this bound 
state. 
A most challenging problem in transferrin chemistry 
is the identification of mechanisms by which transferrin 
is induced to release iron (7). Reduction of Fe3+ to ferrous 
iron (Fe”), which binds weakly to transferrin, is one 
mechanism for the release of free iron from transferrin 
(3, 4, 8). The susceptibility of transferrin-bound Fe3+ to 
reduction can be enhanced by multiple factors. Under 
conditions of increasing hydrogen ion concentration, the 
Fe3+ . transferrin . bicarbonate complex experiences a 
conformational change, resulting in a decrease in binding 
affinity of transferrin for iron (2, 9-11). Theoretically, 
Fe3+, which is buried in the protein at physiologic pH 
(7.4), becomes more accessible to reduction, following 
conformational changes resulting from interaction of 
transferrin with hydrogen ion (12-14). 
Phagocytic cells, including human polymorphonuclear 
leukocytes (PMNs),’ can release reactive oxygen metab- 
olites including superoxide anion (0;) following activation 
(15). Although there have been extensive in vitro studies 
examining the ability of reducing agents like sodium di- 
* Abbreviations used: PMN, polymorphonuclear leukocytes; HBSS, 
Hanks’ balanced salt solution: PBS, phosphate-buffered saline; SOD, 
superoxide dismutase; BPS, bathophenanthroline disulfonate; NTA, 
nitrilotriacetic acid; BSA, bovine serum albumin; TRF, transferrin; 
APOTRF, apotransferrin. 
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thionite (3), thioglycolate (3), and ascorbate (6) to facil- 
itate the release of Fe2+ from transferrin, the ability of 
PMN-derived 0, to facilitate the release of Fe2+ from 
Fe3+. transferrin . HCOZ- has not been thoroughly inves- 
tigated (16). In the following in uitro experiments we as- 
sessed the effect of iron saturation and decreasing pH on 
the ability of PMN-derived 0, to facilitate the release of 
Fe2+ from transferrin. 
MATERIALS AND METHODS 
Chemicals. All chemicals were purchased from Sigma Chemical Co. 
(St. Louis, MO) unless otherwise noted. 
Isolation of PMNs. Human PMNs were isolated from titrated blood 
as described previously (17,18). Briefly, PMNs were obtained from whole 
blood by Ficoll Hypaque (Pharmacia, Piscataway, NJ) density gradient 
centrifugation, dextran sedimentation, and hypotonic lysis of red cells. 
Purified PMNs were resuspended at lo6 cells/ml in Hanks’ balanced 
salt solution (HBSS). In selected experiments, cells were suspended in 
phosphate-buffered saline (PBS) containing 1 mM calcium, 0.5 mM 
magnesium, and 0.1% dextrose. 
Superoxide anion generation. Extracellular superoxide anion gen- 
eration by PMNs was measured spectrophotometrically by the super- 
oxide dismutase (SOD) inhibitable reduction of ferricytochrome c (19). 
PMNs (3 X lOa) were suspended in 3 ml HBSS containing 160 pM fer- 
ricytochrome c and stimulated with phorbol myristate acetate [PMA 
(100 rig/ml final)]. The rate of extracellular 0; generated/min was de- 
termined by the change in absorbance/min at 550 nm of PMN cell 
supernatants f SOD (90 U/ml final). The difference in absorbance per 
sample + SOD divided by the extinction coefficient (21.1 X lo3 Me’ 
cm-‘) yielded nanomoles OF/lo6 PMNs/min. All spectrophotometric 
measurements were conducted with a dual beam Cary 210 spectropho- 
tometer (Varian Instruments, Palo Alto, CA). The lower limit of AU 
change that can be measured accurately under conditions in these ex- 
periments is 0.001. 
Release of F$’ from holosaturuted transferrin. The release of Fe*+ 
from holosaturated transferrin by PMN-derived 0; was monitored 
spectrophotometrically (535 nm) as described previously (3). Briefly, 
unstimulated and stimulated [PMA (100 rig/ml final)] PMNs (106) were 
incubated in 1 ml HBSS containing iron-saturated transferrin (0.060 
mM final), bathophenanthroline disulfonate (BPS) (0.50 mM final) with 
and without SOD (90 U/ml final) for 20 min in a 37°C shaking water 
bath. Catalase (100 U/ml) was included in the reaction to inhibit the 
potential oxidation of Fe2+ by hydrogen peroxide. The samples were 
centrifuged (3OOg, 10 min, 20°C) and the cell supernatants removed. 
The Op-dependent release of Fe’+ was determined by the difference in 
absorbance at 535 nm of samples with and without SOD. The difference 
in absorbance was divided by the extinction coefficient (2.214 X lo4 Iv-’ 
cm-‘) yielding nanomoles Fe2+/106 PMNs/20 min. In selected experi- 
ments, holosaturated transferrin was initially dialyzed against 0.1 M 
sodium perchlorate (NaCIO,) as described previously (20) to remove 
any contaminating iron and dialyzed against PBS prior to use. 
Preparation of transferrin at physiological levels of iron satura- 
tion. Transferrin at physiologic levels of iron saturation (i.e., 30-44%) 
was prepared according to previously published methods (21) with minor 
modifications. Briefly, a 0.2 mM Fe3+ stock solution was prepared by 
reacting Fe3+ with nitrilotriacetic acid (NTA) at a ratio of 1:4 (21). 
Sideroferrin (0.015 mM) in 0.01 M Tris buffer (pH 7.4) was incubated 
with Fe * NTA (0.010 mM final) in the presence of sodium bicarbonate 
(NaHCO,; 10 mM final) for 30 min at 22°C. The percentage iron sat- 
uration of the transferrin was determined by comparison of the change 
in absorbance at 470 nm of the solution to that of holosaturated trans- 
ferrin (0.015 mM). The partially iron-saturated transferrin was dialyzed 
in PBS (pH 7.4) containing NaClO, for 24 h to chelate any extraneous 
iron (20). The transferrin solution containing NaClO, was dialyzed 
against PBS for 12 h concentrated in an Amicon concentrator, and 
dialyzed again in PBS (pH 7.4) containing 1 mM calcium, 0.5 mM mag- 
nesium, and 0.1% dextrose for 12 h. The protein content of the partially 
iron-saturated transferrin was assessed via the Bradford protein assay 
with bovine serum albumin (BSA) as a standard (22). Transferrin, at 
physiologic levels of iron saturation, was then utilized in assays using 
methodology previously described for holosaturated transferrin. 
Release ofFe3’ from transferrin. The release of Fe3+ from transferrin 
by conditioned media from unstimulated and PMA-stimulated PMNs 
was determined. PMNs (2.5 X 106/ml) were incubated with SOD (90 
U/ml final) and catalase (100 U/ml final) in the presence and absence 
of PMA (100 rig/ml final) for 10 min. Following centrifugation (3OOg, 
10 min, 22’C), PMN-conditioned media (lo6 cell equivalents) was in- 
cubated with transferrin (0.060 mM final) at specific pH values in the 
presence of deferoxamine (10 mM final) in a shaking water bath (37”C, 
20 min). The release of ferric iron from transferrin was monitored spec- 
trophotometrically by the decrease in absorbance of transferrin at 295 
nm, as previously described (6). 
Statistical analysis. All data represent the mean f the standard error 
of the mean (SEM) from at least three experiments. PMNs used in a 
given experiment were from a single healthy donor. Different donors 
were used in each experiment. A one factor analysis of variance (ANOVA) 
and Scheffe F test were performed to compare differences between 
treatment groups. In appropriate experiments, the Student’s paired t 
test was used to compare differences between treatment groups. (P 
< 0.05 was considered significant). 
RESULTS 
The ability of PMNs to secrete 0, at pH 7.4 in response 
to stimulation with PMA (100 rig/ml final) was deter- 
mined. While unstimulated PMNs secreted negligible 
amounts of 0, (4 nmol/min), following stimulation with 
PMA (100 rig/ml final), the initial rate of 0; secreted by 
lo6 PMNs was 12.04 -t 0.77 nmol O;/min (n = 8). This 
is consistent with previously published reports (23). The 
effect of the presence of transferrin on PMN respiratory 
burst was also determined. Results of these experiments 
(data not shown) indicate that inclusion of transferrin in 
the reaction does not alter the rate of oxygen consumption 
by unstimulated or PMA-stimulated PMNs. 
The ability of unstimulated and PMA-stimulated 
PMNs to facilitate the release of Fe2+ from holosaturated 
transferrin at pH 7.4 was assessed (Table I). While un- 
stimulated PMNs facilitated the release of minimal 
amounts of iron (0.11 nmol) from holosaturated trans- 
ferrin (98%), stimulation of PMNs with PMA (100 ng/ 
ml, final) enhanced the release of Fe2+ from transferrin 
approximately eightfold. Dialysis of holosaturated trans- 
ferrin in 0.1 M NaCIO, prior to use did not significantly 
alter the ability of PMA-stimulated PMNs to facilitate 
the release of Fe2+ from transferrin (data not shown). 
Similar results were also obtained in reactions in the ab- 
sence of catalase (data not shown). Addition of SOD (90 
U/ml) to PMA-stimulated PMNs prior to incubation re- 
sulted in the release of a small amount of iron (0.17 nmol) 
from holosaturated transferrin, while incubation of PMA- 
stimulated PMNs with heat-inactivated SOD (8O”C, 60 
min) failed to significantly inhibit the release of Fe2+ from 
transferrin by PMA-stimulated PMNs (P > 0.05). These 
results suggest that the release of Fe2+ from holosaturated 
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TABLE I 
Effect of Stimulated PMNs on Fe’+ Release 
From Transferrin at pH 7.4 
Cells 
Transferrin Nanomoles % Total 
(% iron saturation) Fe’+ released iron released 
PMN 
PMN + PMA 
PMN + PMA 
98 0.11 2 0.03 0.09 
98 0.82 + 0.09 * 0.70 
+ SOD 
PMN + PMA 
98 0.17 + o.oo** 0.14 
+ Heated SOD 
PMN 
PMN + PMA 
98 0.63 + 0.09 0.54 
32 0.06 2 0.06 0.16 
32 0.07 + 0.07 0.18 
Note. Iron-saturated transferrin [0.060 mM transferrin; 98% saturated 
(117.6 WM iron total)] and partially iron-saturated transferrin [O.OSO 
mM transferrin; 32% saturated (38.4 pM iron total)] were incubated with 
10s unstimulated and stimulated [PMA (100 rig/ml)] PMNs and nmol 
of Fe*’ released/20 min were determined. The effect of SOD (90 U/ml) 
and heat-inactivated SOD [8O”C, 60 min (90 U/ml)] on the release of 
Fe’+ from holosaturated transferrin by stimulated PMNs was also as- 
sessed. 
* Significantly different from unstimulated PMN. 
** Significantly different from PMA-stimulated PMNs (ANOVA; P 
< 0.05). 
transferrin by PMNs was dependent on PMN-derived 
0,. Furthermore, the ability of PMNs to competitively 
bind Fe’+, resulting in a potential decrease in the amount 
of Fe2+ bound to BPS and an underestimation of the 
amount of Fe’+ released from transferrin by PMN-derived 
0; was also determined. PMNs were incubated with BPS 
and a known concentration of Fe’+. The amount of Fe2+ 
chelated to BPS in PMN-conditioned media was then 
compared to that bound to BPS that had been incubated 
with the same concentration of Fe’+ in the absence of 
PMNs. Results of these experiments (data not shown) 
indicate that the same concentration of Fe’+ is bound to 
BPS in reactions in the presence and absence of PMNs, 
indicating that PMNs do not bind significant amounts 
of Fe2+. 
The ability of PMN-derived extracellular 0; to facil- 
itate the release of Fe2+ from transferrin at physiologic 
levels of iron saturation (32%) and pH 7.4 was determined. 
In contrast to holosaturated transferrin, incubation of 
unstimulated or PMA-stimulated PMNs with partially 
iron-saturated transferrin failed to increase the release 
of Fe2+ at physiologic pH (Table I). 
The effect of decreasing the pH (by addition of HCl) 
on the release of Fe’+ from transferrin was assessed (Table 
II). No Fe2+ is released from transferrin at pH 6.6 or 6.2 
in the absence of a reducing agent. While incubation of 
unstimulated PMNs at either pH 6.6 or 6.2 with holo- 
saturated transferrin (98%) resulted in the release of 
minimal amounts of Fe2+ (<l nmol), the amount of Fe2+ 
released from holosaturated transferrin at these mildly 
acidic pHs was markedly enhanced following incubation 
with PMA-stimulated PMNs. Fe’+ release was inhibited 
following incubation of PMNs with SOD. In contrast, 
addition of heat-inactivated SOD failed to significantly 
inhibit Fe’+ release from holosaturated transferrin by 
PMA-stimulated PMNs at pH 6.6 and 6.2 (data not 
shown). Incubation of PMA-stimulated PMNs at pH 6.6 
or 6.2 with transferrin at physiologic levels of iron satu- 
ration (39.63% + 2.02) resulted in the release of 1.15 
+ 0.27 nmol and 1.82 4 0.48 nmol of Fe’+, respectively 
(Table II). The increased release of Fe’+ from partially 
TABLE II 
Effect of Decreasing the pH and Superoxide Dismutase on Fe2+ Release by PMNs 
Transferrin 
Cells (% iron saturation) PH Nanomoles Fe’+ released % Total iron released 
PMN 98 6.6 0.77 f 0.27 0.65 
PMN + PMA 98 6.6 6.66 f 0.59* 5.66 
PMN + PMA + SOD 98 6.6 0.41 f 0.17** 0.35 
PMN 98 6.2 0.54 t 0.27 0.46 
PMN t PMA 98 6.2 5.53 f 0.69, 4.70 
PMN + PMA t SOD 98 6.2 0.48 I 0.26** 0.41 
PMN 39 6.6 0.28 -t 0.08 0.60 
PMN + PMA 39 6.6 1.15 k 0.27* 2.46 
PMN + PMA + SOD 39 6.6 0.11 f 0.11** 0.24 
PMN 39 6.2 0.38 f 0.07 0.81 
PMN + PMA 39 6.2 1.82 If- 0.48* 3.89 
PMN + PMA + SOD 39 6.2 0.07 f 0.04** 0.15 
Note. Iron-saturated transferrin [O.OSO mM, 98% saturated (117.6 pM iron total)] and partially saturated transferrin [O.OSO mM, 39% saturated 
(46.80 FM iron total)] were incubated with 10” unstimulated and stimulated [PMA (100 rig/ml)] PMNs at pH 6.6 and 6.2 and nmol of Fe’+ 
released/20 min were determined. The effect of SOD (90 U/ml) on the release of Fe ‘+ from transferrin by stimulated PMNs was also assessed. 
* Significantly different from unstimulated PMNs. 
** Significantly different from PMA-stimulated PMNs (ANOVA; P < 0.05). 
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FIG. 1. Effect of decreasing pH on nanomoles of iron released from 
transferrin and superoxide anion production by PMA-stimulated PMNs. 
n , nmole Fe*+ released from holosaturated transferrin IO.060 mM; 98% 
iron saturated (117.6 pM iron total)]; l?J, nmol Fe’+ released from partially 
saturated transferrin [O.OSO mM; 32-34% iron saturated (38.4-40.8 FM)], 
0, %02- generated by lOa PMA-stimulated PMNs (100% = 167 nmol 
O;/lOs PMA-stimulated PMNs/20 min at pH 7.4). 
saturated transferrin at pH 6.6 and 6.2 was also inhibited 
by SOD (Table II) and occurred despite a pH-dependent 
decrease in extracellular 0, generation (Fig. 1). 
In further experiments, a more detailed study on the 
effect of decreasing pH on the release of ferrous iron from 
transferrin at physiologic levels of iron saturation was 
performed. For these studies, PMA-stimulated neutro- 
phils were incubated with transferrin at physiologic levels 
of iron saturation (39% saturated) at 0.2 pH increments 
between pH 6.6 and 7.4. At pH 6.8,0.59 nmol of Fe’+ was 
released by PMA-stimulated neutrophils compared to 0.28 
nmol of Fe2+ released from transferrin in the presence of 
unstimulated neutrophils. At pH 7.0, 7.2, and 7.4 PMA- 
stimulated PMNs did not facilitate the release of en- 
hanced amounts of Fe’+ from transferrin. Results of these 
experiments indicate that neutrophil-derived superoxide 
ion facilitates the release of enhanced amounts of ferrous 
iron from transferrin at pHs equal to and less than 
pH 6.8. 
To determine if PMN-derived 0, facilitated the release 
of Fe3+ from transferrin, unstimulated and PMA-stimu- 
lated PMNs were incubated with holosaturated transfer- 
rin and deferoxamine (a Fe 3+ chelator) in the presence 
and absence of SOD. The release of Fe3+ from holosatu- 
rated transferrin was assessed spectrophotometrically by 
the formation of a Fe3+-deferoxamine complex in PMN- 
conditioned media. Results of these experiments (data 
not shown) indicate that equivalent amounts of Fe3’ are 
released from transferrin by unstimulated and PMA- 
stimulated PMNs. To further address the ability of se- 
cretory products derived from PMA-stimulated PMNs to 
enhance Fe3+ release from transferrin, conditioned media 
from unstimulated and PMA-stimulated PMNs was in- 
cubated with iron-saturated transferrin (98%) and par- 
tially saturated transferrin (34% + 1.73) in the presence 
of deferoxamine (Table III). As indicated by the decrease 
in absorbance of transferrin at 295 nm, conditioned media 
from unstimulated or PMA-stimulated PMNs was equally 
effective in facilitating the release of Fe3+ from transferrin, 
suggesting that secretory products of stimulated PMNs 
do not effect the release of Fe’+ from transferrin at mildly 
acidic pH by enhancing Fe3+ labilization. Furthermore, 
this data suggests that approximately four times more 
labile Fe3+ is available from holosaturated transferrin than 
from partially saturated transferrin at pH 7.4. As the pH 
TABLE III 
Effect of PMN Supernatants on Fe3+ Release from Transferrin 
PMN-Conditioned 
media % Saturation PH 
Decrease in 
absorbance 295 nm 
Unstimulated 98 1.4 0.095 + 0.048 
PMA Stimulated 98 7.4 0.122 -+ 0.027 NS 
Unstimulated 98 6.6 0.631 f 0.065 
PMA Stimulated 98 6.6 0.549 f 0.048 NS 
Unstimulated 98 6.2 0.836 k 0.049 
PMA Stimulated 98 6.2 0.800 2 0.044 NS 
Unstimulated 34 7.4 0.025 f 0.025 
PMA Stimulated 34 7.4 0.033 k 0.009 NS 
Unstimulated 34 6.6 0.182 + 0.018 
PMA Stimulated 34 6.6 0.158 + 0.024 NS 
Unstimulated 34 6.2 0.182 + 0.015 
PMA Stimulated 34 6.2 0.152 + 0.043 NS 
Note. Iron-saturated transferrin [O.OSO mM, 98% saturated (117.6 pM 
iron total)] and partially saturated transferrin [0.060 mM, 34% saturated 
(40.8 fiM iron total)] were incubated with conditioned media from un- 
stimulated and stimulated [PMA (100 rig/ml)] PMNs (lo6 equivalents) 
in the presence of deferoxamine (10 mM final) and the decrease in ab- 
sorbance (295 nm) of transferrin/20 min was assessed. NS = no signif- 
icant difference between unstimulated and stimulated PMN-conditioned 
media. 
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is decreased, significantly more Fe3+ is labilized from 
transferrin due to pH-dependent conformational changes 
in the transferrin . iron. bicarbonate complex (6). 
DISCUSSION 
PMN-derived 0, facilitated the release of Fe’+ from 
iron-saturated transferrin at physiologic pH, yet failed to 
facilitate the release of Fe’+ from transferrin at physio- 
logic levels of iron saturation at pH 7.4. This is in agree- 
ment with a previous report by Biemond et al. (16) which 
suggests that at physiologic pH, stimulated PMNs failed 
to mobilize iron from partially saturated (60%) transfer- 
rin. Furthermore, previous studies at physiologic pH by 
Aruoma et al. (24) provide indirect evidence that is con- 
sistent with the hypothesis that O;, in the presence of 
EDTA, only minimally mobilizes iron from saturated 
transferrin. Other studies have shown that 0; does not 
directly react with 50% iron-saturated transferrin (25). 
As a result of these findings, the role of transferrin as a 
source of iron for biological reactions at sites of acute 
inflammation has been questioned (16, 26). 
As an extension of these studies, we determined the 
effect of decreasing the pH on the ability of PMN-derived 
0, to facilitate the release of Fe’+ from holosaturated 
transferrin and from transferrin at physiologic levels of 
iron saturation. It has been demonstrated that iron release 
from transferrin can be modulated by several factors in- 
cluding pH (2, 3, 6, 27). As the pH is decreased, the sta- 
bility of the Fe3+ transferrin . bicarbonate complex de- 
creases, rendering the metal susceptible to reduction (3). 
We found that decreasing the pH to 6.6 and 6.2 facilitated 
the release of Fe’+ from holosaturated transferrin by un- 
stimulated and PMA-stimulated PMNs. The enhanced 
release of Fe’+ under mildly acidic conditions occurred 
despite a decrease in the amount of 0; generated by PMA- 
stimulated cells, indicating an increased efficiency in 
O,-dependent reduction of Fe3+. Our results are consistent 
with those of Saito et al. (26) who concluded that the 
amount of Fe’+ released from holosaturated transferrin 
by xanthine-xanthine oxidase-derived 0; was greatly en- 
hanced by decreasing the pH. 
Of potentially greater biological significance, results of 
our studies indicate that decreasing the pH facilitated the 
release of Fe” from partially saturated transferrin by 
PMN-derived 0;) achieving concentrations in our assay 
system of greater than 1 pM. Since the plasma concen- 
tration of transferrin is approximately 25-35 PM (28), 
these data suggest that similar concentrations of Fe’+ may 
be released from transferrin at sites of acute inflammation 
due to PMN-derived O,-dependent reduction of labilized 
Fe3+. Furthermore, comparable amounts of Fe’+ were re- 
leased from partially saturated transferrin by PMA-stim- 
ulated PMNs at pH 6.6 and 6.2, despite a progressive 
decrease in the amount of 0; generated by PMA-stimu- 
lated PMNs as the acidity increased. This indicates an 
increased efficiency of Fe’+ release from partially satu- 
rated transferrin by PMN-derived 0, in mildly acidic 
conditions similar to that observed with holosaturated 
transferrin. Thus, we suggest that, at sites of tissue injury, 
the release of Fe2+ from transferrin at physiologic levels 
of iron saturation by PMN-derived 0; is dependent on 
the hydrogen ion-mediated destabilization of the 
Fe3+. transferrin . bicarbonate complex making the Fe3+ 
more susceptible to reduction. 
Inflammation/ischemia 
H+ PMN-derived 02 
Fe3+. TRF . CO:- ’ [Fe3+=TRF.C0im] J APOTRFCOZ- + Fe*+, 
where TRF and APOTRF are transferrin and apotrans- 
ferrin, respectively, and [Fe 3+ . TRF * CO,“- ] indicates the 
destabilized conformational state of transferrin. 
In conclusion, transferrin at physiologic levels of iron 
saturation can serve as a source of Fe’+ for participation 
in biological reactions including propagation of lipid per- 
oxidation and generation of hydroxyl radical formation 
following reaction with phagocytic cell-derived hydrogen 
peroxide. The restriction of this effect to conditions of 
mildly acidic pH and the presence of a reducing agent 
like PMN-derived 0, limits its pathophysiologic role to 
disease processes that result in a significant decrease in 
tissue pH [e.g., sites of inflammation (29), ischemic injury 
(30)] or within the microenvironment of activated phago- 
cytic cells where the pH at the cell surface is less than 
6.0 (31). 
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